NCT01540864View on ClinicalTrials.gov

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
ObesityOverweight
Interventions
DRUG

HPP404

Administered orally once daily for 26 weeks

DRUG

Placebo

Administered orally once daily for 26 weeks

Trial Locations (10)

10065

Site 2, New York

23294

Site 6, Richmond

23502

Site 7, Norfolk

27265

Site 5, High Point

28277

Site 1, Charlotte

30909

Site 11, Augusta

40213

Site 12, Louisville

46383

Site 3, Valparaiso

55114

Site 10, Saint Paul

02601

Site 9, Hyannis

Sponsors
All Listed Sponsors
lead

High Point Pharmaceuticals, LLC.

INDUSTRY